

Kentaro Tanaka

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9384827/kentaro-tanaka-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

2,112
citations

21
h-index

45
g-index

80
ext. papers

2,600
ext. citations

5
avg, IF

4.28
L-index

#	Paper	IF	Citations
75	Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. <i>Immunity</i> , 2009 , 30, 80-91	32.3	646
74	Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. <i>Immunity</i> , 2003 , 19, 437-50	32.3	193
73	Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. <i>Journal of Immunology</i> , 2008 , 180, 3746-56	5.3	145
72	Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. <i>Journal of Immunology</i> , 2007 , 179, 2170-9	5.3	90
71	Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. <i>Journal of Immunology</i> , 2005 , 174, 4325-32	5.3	82
70	Generation of ROR γ Antigen-Specific T Regulatory 17 Cells from Foxp3 Precursors in Autoimmunity. <i>Cell Reports</i> , 2017 , 21, 195-207	10.6	73
69	Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. <i>International Immunology</i> , 2008 , 20, 753-62	4.9	65
68	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 731-770	4.2	63
67	Batf is important for IL-4 expression in T follicular helper cells. <i>Nature Communications</i> , 2015 , 6, 7997	17.4	62
66	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. <i>Lung Cancer</i> , 2018 , 118, 36-40	5.9	51
65	Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. <i>Lung Cancer</i> , 2018 , 115, 116-120	5.9	50
64	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring mutations. <i>Oncotarget</i> , 2017 , 8, 68123-68130	3.3	47
63	The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2006 , 290, L971-7	5.8	42
62	Trim33 mediates the proinflammatory function of Th17 cells. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1853-1868	16.6	31
61	Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by β nicotinic acetylcholine receptor-mediated activation in PC9 cells. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 719-25	8.9	30
60	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. <i>Lung Cancer</i> , 2020 , 145, 18-26	5.9	26
59	Pulmonary suppressor of cytokine signaling-1 induced by IL-13 regulates allergic asthma phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 992-8	10.2	26

58	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 108, 75-82	5.9	24
57	F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019 , 9, 13362	4.9	24
56	Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. <i>Lung Cancer</i> , 2019 , 130, 5-9	5.9	24
55	Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L) 2020 , 8,		21
54	Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. <i>Lung Cancer</i> , 2017 , 112, 230-231	5.9	21
53	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1217-1225	4.9	19
52	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 926-937	8.9	17
51	CCAAT/enhancer-binding protein β negatively regulates IFN- β expression in T cells. <i>Journal of Immunology</i> , 2014 , 193, 6152-60	5.3	17
50	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018 , 9, 30587-30593	3.3	16
49	Regulation of Pathogenic T Helper 17 Cell Differentiation by Steroid Receptor Coactivator-3. <i>Cell Reports</i> , 2018 , 23, 2318-2329	10.6	16
48	Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. <i>Lung Cancer</i> , 2018 , 120, 98-107	5.9	15
47	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. <i>Thoracic Cancer</i> , 2018 , 9, 1519-1521	3.2	13
46	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021 , 152, 27-33	5.9	12
45	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. <i>Lung Cancer</i> , 2019 , 135, 145-150	5.9	10
44	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. <i>Oncotarget</i> , 2017 , 8, 72127-72132	3.3	9
43	Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. <i>Cancer Science</i> , 2018 , 109, 3657-3661	6.9	9
42	CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. <i>Lung Cancer</i> , 2017 , 113, 72-78	5.9	8
41	IL-6 induced by double-stranded RNA augments allergic inflammation via suppression of Foxp3+ T-cell/IL-10 axis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012 , 46, 740-7	5.7	8

40	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021 , 149, 473-482	7.5	8
39	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. <i>Cancer Science</i> , 2020 , 111, 2482-2487	6.9	7
38	A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study). <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 821-825	2.8	7
37	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 472-476	4.9	6
36	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. <i>Lung Cancer</i> , 2020 , 146, 97-104	5.9	6
35	Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non-small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and had no EGFR mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 31073-31079	2.2	6
34	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. <i>European Journal of Cancer</i> , 2021 , 149, 14-22	7.5	6
33	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With Mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100107	1.4	6
32	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. <i>International Immunology</i> , 2020 , 32, 547-557	4.9	5
31	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2121-2132	8.9	5
30	Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma. <i>Annals of Hematology</i> , 2018 , 97, 359-360	3	4
29	Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. <i>Diagnostics</i> , 2020 , 10,	3.8	4
28	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>European Journal of Cancer</i> , 2021 , 145, 183-193	7.5	4
27	Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers. <i>PLoS ONE</i> , 2021 , 16, e0244354	3.7	4
26	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). <i>Clinical Lung Cancer</i> , 2020 , 21, e592-e596	4.9	3
25	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2475-2486	4.4	3
24	Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021 , 11, 12732	4.9	3
23	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. <i>Lung Cancer</i> , 2018 , 126, 156-161	5.9	3

22	Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy. <i>International Journal of Cancer</i> , 2020 , 147, 2327-2334	7.5	2
21	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. <i>Lung Cancer</i> , 2019 , 138, 58-64	5.9	2
20	Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. <i>Clinical Lung Cancer</i> , 2020 , 21, e21-e24	4.9	2
19	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). <i>Clinical Lung Cancer</i> , 2021 , 22, 147-151	4.9	2
18	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.. <i>Cancer</i> , 2022 ,	6.4	2
17	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019 , 39, 671-677	2.3	1
16	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2021 ,	4.9	1
15	Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 15, 261	1.6	1
14	A measuring method for occupancy of immune checkpoint inhibitors in the cell surface. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 527, 213-217	3.4	1
13	Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 2830-2839	3.2	1
12	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. <i>Lung Cancer</i> , 2021 , 158, 156-161	5.9	1
11	Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. <i>Clinical Lung Cancer</i> , 2021 , 22, e784-e785	4.9	1
10	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8557-8557	2.2	0
9	A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9597-9597	2.2	0
8	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 155, 144-150	5.9	0
7	High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100191	1.4	0
6	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1745-1753	7.4	0
5	A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.. <i>BMC Cancer</i> , 2022 , 22, 503	4.8	0

4	Paraneoplastic Brainstem Encephalitis and Subacute Sensory Neuropathy Presenting Various Neurological Symptoms Associated with Small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2009 , 49, 852-856	0.1
3	Final analysis of a phase II, open label, randomized study of osimertinib versus osimertinib plus carboplatin/pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous EGFR-TKI and whose tumours harbour a T790M mutation (COU-101/17-10001). <i>Journal of Clinical Oncology</i> , 2020 , 38, e1501-e1501	2.2
2	5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017 , 106, 1117-1124	0
1	Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21125-e21125	2.2